Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
130
-
Total 13F shares, excl. options
-
66.6M
-
Shares change
-
-4.27M
-
Total reported value, excl. options
-
$222M
-
Value change
-
-$12.7M
-
Put/Call ratio
-
1.31
-
Number of buys
-
54
-
Number of sells
-
-71
-
Price
-
$3.34
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q4 2020
159 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q4 2020.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 130 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 66.6M shares
of 123M outstanding shares and own 54.05% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (10M shares), BlackRock Inc. (7.74M shares), STATE STREET CORP (6.11M shares), VANGUARD GROUP INC (5.77M shares), GOLDMAN SACHS GROUP INC (3.22M shares), PRUDENTIAL FINANCIAL INC (2.67M shares), ROYCE & ASSOCIATES LP (2.41M shares), HealthInvest Partners AB (1.75M shares), GEODE CAPITAL MANAGEMENT, LLC (1.6M shares), and LSV ASSET MANAGEMENT (1.49M shares).
This table shows the top 130 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.